Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Clinical trial NCT02954523 · TERMINATED

Trial details

NCT number: NCT02954523
Sponsor: Chul Kim
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

EGFR Gene Mutation Nonsmall Cell Lung Cancer

Start date: 2016-10-01
Primary completion: 2018-08-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.